Last10K.com

La Jolla Pharmaceutical Co (LJPC) SEC Filing 8-K Material Event for the period ending Sunday, November 1, 2020

La Jolla Pharmaceutical Co

CIK: 920465 Ticker: LJPC

View differences made from one to another to evaluate La Jolla Pharmaceutical Co's financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 8-K Corporate News to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by La Jolla Pharmaceutical Co.

Continue

Assess how La Jolla Pharmaceutical Co's management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

La Jolla Pharmaceutical Co's Definitive Proxy Statement (Form DEF 14A) filed after their 2020 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors

Continue

Tools

Financial Statements, Disclosures and Schedules

Inside this 8-K Corporate News

Material Contracts, Statements, Certifications & more

La Jolla Pharmaceutical Co provided additional information to their SEC Filing as exhibits

Ticker: LJPC
CIK: 920465
Form Type: 8-K Corporate News
Accession Number: 0001564590-20-051438
Submitted to the SEC: Thu Nov 05 2020 4:58:23 PM EST
Accepted by the SEC: Thu Nov 05 2020
Period: Sunday, November 1, 2020
Industry: Biological Products No Disgnostic Substances
Events:
  1. Accountant Change
  2. Financial Exhibit

External Resources:
Stock Quote
Social Media

Bookmark the Permalink:
https://last10k.com/sec-filings/ljpc/0001564590-20-051438.htm